To determine whether our in vitro observations were also seen in vivo, we evaluated the effect of the combination treatment on xenoengrafted primary MLL-translocated AML cells exhibiting a substantial disease burden. The gene discussed is KMT2A; the disease is acute myeloid leukemia.